Patents by Inventor Akihiro Takemiya

Akihiro Takemiya has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Hydroamination of Alkenes
    Publication number: 20120190854
    Abstract: A method includes reacting an amino group, a composition including rhodium and an organic ligand, and a substrate having structural formula (I) in a reaction mixture. R1 is an organic group including a sp3 carbon atom bonded to CA. R2 is selected from the group consisting of hydrogen, methyl, and an organic group including a sp3 carbon atom bonded to CA. R3 and R4 independently are selected from the group consisting of hydrogen, methyl, and an organic group including a sp3 carbon atom bonded to CB. The method further includes forming a hydroaminated product in the reaction mixture.
    Type: Application
    Filed: April 5, 2012
    Publication date: July 26, 2012
    Applicant: The Board of Trustees of the University of Illinois
    Inventors: Akihiro Takemiya, Zhijian Liu, John F. Hartwig
  • Indazole compound and pharmaceutical use thereof
    Patent number: 7994196
    Abstract: The present invention can provide a cancer treatment drug containing, as an active ingredient, a substance selected from the group consisting of an indazole compound of the following formula (I), a pharmaceutically acceptable salt, a hydrate, a water adduct and a solvate:
    Type: Grant
    Filed: February 10, 2005
    Date of Patent: August 9, 2011
    Assignee: Mitsubishi Tanabe Pharma Corporation
    Inventors: Akihiro Takemiya, Masahiro Nakajo, Hisae Oshima, Tomotaka Yanagi, Mami Mochizuki, Hideo Nakamura
  • Hydroamination of Alkenes
    Publication number: 20090156824
    Abstract: A method includes reacting an amino group, a composition including rhodium and an organic ligand, and a substrate having structural formula (I) in a reaction mixture. R1 is an organic group including a sp3 carbon atom bonded to CA. R2 is selected from the group consisting of hydrogen, methyl, and an organic group including a sp3 carbon atom bonded to CA. R3 and R4 independently are selected from the group consisting of hydrogen, methyl, and an organic group including a sp3 carbon atom bonded to CB. The method further includes forming a hydroaminated product in the reaction mixture.
    Type: Application
    Filed: October 14, 2008
    Publication date: June 18, 2009
    Applicant: BOARD OF TRUSTEES OF UNIVERSITY OF ILLINOIS
    Inventors: Akihiro Takemiya, Zhijian Liu, John F. Hartwig
  • Indazole compound and pharmaceutical use thereof
    Publication number: 20070173537
    Abstract: The present invention can provide a cancer treatment drug containing, as an active ingredient, a substance selected from the group consisting of an indazole compound of the following formula (I), a pharmaceutically acceptable salt, a hydrate, a water adduct and a solvate:
    Type: Application
    Filed: February 10, 2005
    Publication date: July 26, 2007
    Applicant: Mitsubishi Pharma Corporation
    Inventors: Akihiro Takemiya, Masahiro Nakajo, Hisae Oshima, Tomotaka Yanagi, Mami Mochizuki, Hideo Nakamura
  • Purine derivative dihydrate, drugs containing the same as the active ingredient and intermediate in the production thereof
    Patent number: 6919455
    Abstract: A compound represented by the following formula (I), or a salt thereof: where X is a halogen atom or a group represented by —S—(CH2)n—A, —SO—(CH2)m—B, —SO2—(CH2)m —B, —OSO2—(CH2)m—B, —OCO—(CH2)m—B or —OPO(OR)—(CH2)m—B, wherein n represents an integer of 0-4, A represents an optionally substituted aromatic hydrocarbon group or an optionally substituted heterocyclic residue having 1 to 4 hetero atoms selected from an oxygen atom, sulfur atom and nitrogen atom and having 5 to 10 ring-constituent atoms, m represents an integer of 0-4, B represents an optionally substituted alkyl group, an optionally substituted aromatic hydrocarbon group or an optionally substituted heterocyclic residue having 1 to 4 hetero atoms selected from an oxygen atom, sulfur atom and nitrogen atom and having 5 to 10 ring-constituent atoms, and R represents an optionally substituted alkyl group.
    Type: Grant
    Filed: August 1, 2003
    Date of Patent: July 19, 2005
    Assignee: Mitsubishi Chemical Corporation
    Inventors: Kouichi Sekiya, Akihiro Takemiya
  • Purine derivative dihydrate, drugs containing the same as the active ingredient and intermediate in the production thereof
    Publication number: 20040077665
    Abstract: Dihydrate of 4-[[9-[(3-cyclopentyloxy-4-methoxy)benzyl]-6,8-dimethylpurin]-2-yl-3-oxypropyl]pyridine N-oxide, drugs containing the same and a compound useful as an intermediate in the production of this dihydrate.
    Type: Application
    Filed: August 1, 2003
    Publication date: April 22, 2004
    Applicant: Mitsubishi Chemical Corporation
    Inventors: Kouichi Sekiya, Akihiro Takemiya
  • Purine derivative dihydrate, drugs containing the same as the active ingredient and intermediate in the production thereof
    Patent number: 6660745
    Abstract: Dihydrate of 4-[[9-[(3-cyclopentyloxy-4-methoxy)benzyl]-6,8-dimethylpurin]-2-yl-3-oxypropyl]pyridine N-oxide, drugs containing the same and a compound useful as an intermediate in the production of this dihydrate. Because of having a phosphodiesterase IV inhibitory effect, this dihydrate is useful as a preventive and/or remedy for asthma, chronic obstructive lung disease and/or other inflammatory diseases.
    Type: Grant
    Filed: January 9, 2002
    Date of Patent: December 9, 2003
    Assignee: Mitsubishi Chemical Corporation
    Inventors: Kouichi Sekiya, Akihiro Takemiya, Masahiro Ohshima